The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

694

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant
DRUG: Exemestane

Sponsor

AstraZeneca